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ABSTRACT
Amplification or overexpression of MYCN is involved in development and 
maintenance of multiple malignancies. A subset of these tumors originates from 
neural precursors, including the most aggressive forms of the childhood tumors, 
neuroblastoma and medulloblastoma. In order to model the spectrum of MYCN-
driven neoplasms in mice, we transgenically overexpressed MYCN under the control 
of the human GFAP-promoter that, among other targets, drives expression in neural 
progenitor cells. However, LSL-MYCN;hGFAP-Cre double transgenic mice did neither 
develop neural crest tumors nor tumors of the central nervous system, but presented 
with neuroendocrine tumors of the pancreas and, less frequently, the pituitary gland. 
Pituitary tumors expressed chromogranin A and closely resembled human pituitary 
adenomas. Pancreatic tumors strongly produced and secreted glucagon, suggesting 
that they derived from glucagon- and GFAP-positive islet cells. Interestingly, 3 out of 9 
human pancreatic neuroendocrine tumors expressed MYCN, supporting the similarity 
of the mouse tumors to the human system. Serial transplantations of mouse tumor 
cells into immunocompromised mice confirmed their fully transformed phenotype. 
MYCN-directed treatment by AuroraA- or Brd4-inhibitors resulted in significantly 
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INTRODUCTION
MYC-family proteins are universal amplifiers of 
gene expression in normal cells [1], but display specific 
activity in tumor cells, thus regulating their proliferation, 
apoptosis, growth and differentiation [2]. Ever since 
the identification of MYCN amplification in primary 
neuroblastoma [3], an oncogenic role of MYCN has been 
assumed. MYCN is able to promote proliferation and 
repress differentiation, which promotes tumor growth in 
numerous malignancies. Under physiological conditions, 
expression of MYCN is tightly controlled and subject 
to rapid turnover due to phosphorylation-dependent 
proteasomal degradation in part controlled by Aurora A 
kinase [4]. An enhanced gene dosage due to amplification 
of the associated genomic region is observed in about 
20% of neuroblastoma, giving rise to the most aggressive 
subtype of the disease (reviewed in [5]). Targeted 
overexpression of MYCN in the neural crest, which has 
been shown in different model systems (termed TH-
MYCN and LSL-MYCN;DBH-iCre, respectively) [6] 
[7], results in neuroblastic tumors closely resembling the 
respective human malignancies. Similarly, overexpression 
of mutationally stabilized MYCN in progenitor cells 
of the mouse cerebellum generates MYCN-driven 
medulloblastomas [8]. MYCN is also deregulated in 
many tumors of neuroectodermal origin [9]. In pancreatic 
neuroendocrine tumors (PanNET) the role of MYC 
proteins is largely unknown, although c-MYC has been 
suggested to act as an oncogene in a fraction of acinar 
cell carcinomas [10] and ductal adenocarcinomas [11]. 
PanNETs, which synthesize and secrete hormones, are 
hormonally syndromic or non-syndromic. Those that are 
syndromic may produce clinical conditions, such as the 
insulinoma syndrome, gastrinoma syndrome (also known 
as Zollinger-Ellison syndrome), glucagonoma syndrome 
and VIPoma syndrome (also known as Verner-Morrison 
syndrome, ordered by declining frequency, for review see 
[12],[13]). Until recently, the existing mouse models for 
glucagonoma were established by conditional deletion of 
tumor-suppressor genes including MEN1 or by combined 
loss of p53 and Rb [14,15]. These model systems used 
insulin-promoter or renin-promoter driven expression 
of Cre recombinase, respectively, to induce target gene 
deletion. However, no driving oncogene such as MYCN 
has been linked to tumor formation in these mice. 
For a long time, MYCN was considered as a poor 
therapeutic target. However, development of inhibitors 
targeting Brd4 (bromodomain containing 4) and AuroraA 
kinase paved new avenues for interference with MYCN 
function [16,17]. JQ1 abrogates Brd4-functions and 
inhibited tumor progression in xenograft models [18] 
as well as in the recently developed LSL-MYCN;DBH-
iCre neuroblastoma mouse model [7]. MLN 8237, which 
promotes MYCN degradation by AuroraA functions, 
prolongs the survival of mice in the TH-MYCN model 
of neuroblastoma [17] and repressed cell viability of 
neuroblastoma cells in vitro [7].
In this study we present a novel mouse model for 
MYCN induced tumors by targeting MYCN-expression 
to hGFAP-positive cells. GFAP is a protein widely 
expressed in the developing nervous system as well as 
in neuroendocrine cells in adulthood. We characterize 
the MYCN induced neuroendocrine tumors in mice and 
provide insights into their biology. We further demonstrate 
that newly established stable cell lines and xenografts 
derived from primary mouse tumors are excellent new 
models to evaluate MYCN-targeted therapies.
RESULTS
LSL-MYCN;hGFAP-Cre mice develop abdominal 
and pituitary tumors
Double transgenic LSL-MYCN;hGFAP-Cre mice 
developed malignancies with an incidence of 59% (32/54), 
while none of the control single transgenic animals 
developed tumors (p < 0.0001 for tumor formation, 
Figure 1A). The vast majority of tumors arose between 
6 months and 11 months of age (Figure 1A). Tumors 
were localized either in the abdomen (n = 20) or in the 
head (n = 7). Five mice presented with tumors at both 
sites, but tumor onset did not significantly differ between 
localizations (Figure 1B). Abdominal tumors were found 
in the pancreas, with involvement of the liver observed in 
four animals (Figure 1C, 1D). Head tumors were located 
at the site of the pituitary gland (Figure 1E). Removal 
of the loxP-cassette was detectable in all of the GFAP-
expressing tissues (not shown), and this was confirmed by 
in vivo bioluminescence imaging (Supplemental Figure 
1). Tumors had significantly elevated MYCN mRNA 
levels compared to controls (Figure 1F) and that also held 
true for MYCN protein expression (Figure 1G). Thus, 
targeted MYCN expression in hGFAP-expressing cells of 
transgenic mice results in tumor formation in pancreatic 
and pituitary tissue.
decreased cell proliferation in vitro and reduced tumor growth in vivo. In summary, 
we provide a novel mouse model for neuroendocrine tumors of the pancreas and 
pituitary gland that is dependent on MYCN expression and that may help to evaluate 
MYCN-directed therapies.
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Pancreatic tumors as well as pituitary tumors 
in LSL-MYCN;hGFAP-Cre mice are of 
neuroendocrine origin
Hematoxylin and eosin (H&E) stained sections 
of the pancreas showed well-demarcated tumor nodules 
of varying size that resembled human neuroendocrine 
tumors (Figure 2A). Small tumors appeared to arise from 
pancreatic islet cells (Figure 2B and 2C). Proliferation of 
tumor cells was moderate as reflected by a low percentage 
of Ki-67 positive cells (data not shown). Tumor cells were 
positive for chromogranin A (Figure 2D) and glucagon 
(Figure 2E), while insulin staining was negative (Figure 
Figure 1: Tumor development in LSL-MYCN;hGFAP-Cre double transgenic mice. A. Kaplan-Meier analyses of transgenic 
(tg/tg) tumor bearing mice compared with their littermate wild type controls (wt/wt). Tumor formation was detectable only in mice at 
an age of 180 days and older (30/54 = 56%). B. Kaplan-Meier analyses of tumor bearing mice depending on tumor localization. The 
curves represent the survival in groups of animals with isolated pancreatic or head tumors or with tumors in both localizations in the same 
individual. No significant differences in the onset of tumor development were observed as a function of tumor localization. C. Macroscopic 
examination revealed small nodules in the pancreas (white arrow), St: stomach, Li: liver. D. Nodule-like tumors in the pancreas are marked 
by arrows. E. Macroscopic appearance of a mouse brain with a tumor (Tu) adjacent to the pituitary gland. Cb: cerebellum, Cx: cortex. Bars, 
C-E: 0.1 cm. F. qRT-PCR reveals low expression of MYCN in control tissue and significantly higher expression of MYCN in tumors (p < 
0.05). G. Western Blot analysis confirms higher MYCN expression in tumors compared with normal control tissue (i.e. tumor-free brain 
of the same mouse).
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2F). The corresponding mice were found to have elevated 
glucagon serum levels (Figure 2G), while insulin levels 
were in physiological range (data not shown). H&E stained 
sections of the pituitary tumors revealed similarities to 
human pituitary adenomas arising in the anterior part of 
the pituitary gland (Figure 3A-3B). As in the pancreas, 
pituitary tumors were positive for chromogranin A (Figure 
3C). We next analysed the MYCN status in a series of nine 
histologically validated human PanNETs to check whether 
this oncogene is also expressed in the human disease. 
Here, comparison of tumor and surrounding normal 
tissue verified MYCN, but not c-MYC mRNA expression 
in three of the nine tumors analysed (Figure 3D), while 
neither MYCN nor c-MYC amplifications were detectable. 
These findings indicate that targeting MYCN expression to 
GFAP-positive cells cause glucagon-producing pancreatic 
neuroendocrine tumors and pituitary adenomas in 
transgenic mice and that MYCN expression is detectable 
in a subset of human PanNETs.
Transcriptomes of murine MYCN-driven 
neuroendocrine tumors show patterns of 
canonical MYC-related mRNA signatures
Next, we wanted to identify disease associated 
transcriptional patterns by comparing mRNA profiles 
obtained from normal murine pancreas [19] with 
those from pancreatic and pituitary tumors of LSL-
MYCN;hGFAP-Cre mice. Using principle component 
Figure 2: Immunohistochemistry reveals neuroendocrine origin of tumors in LSL-MYCN;hGFAP-Cre mice. A. 
H&E staining of a pancreatic tumor with neuroendocrine features. Bar, 200 µm. B., C. Higher magnification shows close-up reveals 
localization of the tumor to the site of pancreatic cells. IC: islet cells, Tu: tumor cells. D. Chromogranin A staining confirmed the diagnosis 
of a neuroendocrine tumor. E. Glucagon staining of pancreatic tumors arising in LSL-MYCN;hGFAP-Cre transgenic mice. F. Absence of 
insulin staining in pancreatic tumors. Bars in B-F, 50 µm. G. Glucagon levels in blood plasma of control animals or tumor-bearing LSL-
MYCN;hGFAP-Cre mice.
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analyses, we were able to separate expression patterns 
of pancreatic tumors from pituitary tumors and from 
normal pancreatic control tissue (Figure 4A). Moreover, 
when mRNA profiles from murine MYCN-driven 
neuroblastoma were included [7], all tumors arising 
in LSL-MYCN;hGFAP-Cre mice clustered together, 
while MYCN-induced neuroblastomas were grouped 
separately (PCA2, Supplemental Figure 2). We therefore 
compared the specific MYCN pathway activity score in 
the mRNA profiles of all tumors. This revealed a specific 
MYCN-signature described for MYCN-driven murine 
neuroblastomas also in the pancreatic tumors of LSL-
MYCN;hGFAP-Cre mice (Figure 4B). Furthermore, 
down-regulated mRNAs of the kallikrein peptidase family 
(Klk1, Klk1b3, Klk1b5) and the cholecystokinin receptor 
type A (CCKAR), and expression of cdh2 coding for 
N-cadherin as well as somatostatin (Supplemental Table 1) 
discriminated pancreatic tumors from pancreatic controls. 
Hierarchical clustering of the differentially expressed 
genes then identified a common pattern of gene regulation 
in all tumors arising in the MYCN-GFAP model (Figure 
4C). Thus, mRNA profiling allowed both, the recognition 
of tumor-specific and MYCN-specific signatures in LSL-
MYCN;hGFAP-Cre induced tumors.
Stable cell lines derived from LSL-
MYCN;hGFAP-Cre induced pancreatic tumors 
are susceptible to MYCN-directed small molecule 
inhibition in vitro and in vivo
To establish in vitro systems for functional 
characterization of our newly developed tumor model, 
cells from a pancreatic tumor of a LSL-MYCN;hGFAP-
Cre mouse were isolated and cloned to obtain stable 
cell lines. One of these cell lines, designated Pank4, 
Figure 3: Immunohistochemistry of brain tumors in LSL-MYCN;hGFAP-Cre mice confirmed their neuroendocrine 
origin. A., B. H&E stained sections of tumors arising in the pituitary gland at lower and higher magnification, respectively. C. Positive 
chromogranin A immunostaining of a pituitary tumor. Bars, 50 µm. D. Normalized MYCN mRNA expression in a series of nine human 
PanNETs. MYCN expression was normalized to the expression of β-Actin and this value was set to “1” in the positive control, a human 
neuroblastoma cell line with high MYCN levels due to an amplification of the MYCN oncogene. The horizontal line depicts a threshold of 
5% of MYCN expression in the positive control.
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displayed undifferentiated morphology (Figure 5A) and 
provided a positive luciferase signal in bioluminescence 
imaging (Supplemental Figure 3), indicating activation 
of the transgenic cassette. Pank4 cells were able to grow 
as xenografts in immunocompromised mice. In vivo 
luciferase imaging again indicated expression of the 
transgenic cassette (Figure 5B), which was corroborated 
by detection of the Cre-mediated removal of the floxed 
stop sequence (Supplemental Figure 4). To confirm 
that growth of these tumors was still dependent on the 
expression of the transgenic driver gene, MYCN, animals 
were treated with a Brd4-inhibitor, JQ1, or an Aurora 
kinase inhibitor, MLN 8237, once that Pank4-induced 
xenografts reached a size of 100 mm3. Tumor growth in 
JQ1 and MLN 8237 treated animals was significantly 
reduced compared to DMSO controls (p = 0.05 for 
treatment with JQ1, and p = 0.018 for treatment with 
MLN 8237, Figure 5C). To analyse on-target effects of 
Figure 4 Microarray-derived mRNA profiles obtained from tumors of LSL-MYCN;hGFAP-Cre mice were compared 
to control pancreata. A. Principal component analyses (PCA) revealed that all tumors group according to the site of tumor origin as 
indicated and that these tumor profiles cluster apart from the control profiles (“Pancreas control”). B. MYCN pathway activity scores were 
calculated for all LSL-MYCN;hGFAP-Cre tumor profiles and compared to profiles of MYCN-driven neuroblastoma. C. Hierarchical 
clustering of genes discriminating pancreatic LSL-MYCN;hGFAP-Cre tumors from normal pancreas reveals tumor-specific patterns 
independent of the tumor site origin.
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both treatment modalities, Pank4-induced xenografts 
were treated over a period of three days. After that period, 
tumors were excised and checked for MYCN mRNA and 
protein expression, respectively (Figure 5D-5E). Here, 
significant reduction of MYCN mRNA was observed by 
both treatments. Additionally, MYCN protein levels were 
reduced by both MLN8237 and JQ1. Histological analyses 
revealed significantly less proliferating, Ki-67 positive, 
tumor cells upon targeted treatment (p = 0.04 and p = 
0.036 for treatment with JQ1 or MLN 8237, respectively). 
Moreover, a significant increase in the fraction of 
apoptotic cells was observed for animals treated with JQ1 
(p = 0.012) or with MLN 8237 (p < 0.0001, Figure 5D-
5E). Thus, targeted treatment of xenografts derived from 
Figure 5: A. Morphology of a cell line, designated Pank4, which was derived from a pancreatic tumor of a LSL-MYCN;hGFAP-Cre 
mouse. Bar, 200 µm. B. Xenografts of Pank4 are luciferase-positive in immunocompromised mice. C. Growth curves of xenograft tumors, 
induced by grafting Pank4 cells into immunocompromised mice. Mice were treated either with JQ1, MLN8237 or vehicle. D. Mice bearing 
Pank4-induced xenografts were subjected to forced treatment over three days with either with JQ1, MLN8237 or vehicle (control, “*”: 
p < 0.05; “**”: p < 0.01). Hereafter, tumors were checked for MYCN mRNA expression and E. MYCN protein expression. F. Histology 
of tumors analysed in C. Tumors were stained with H&E, Ki-67 or an antibody detecting cleaved caspase 3. G. Statistical evaluation of 
differentially treated tumors with respect to the fraction of tumor cells staining positive for cleaved Caspase-3 or Ki-67, respectively. 
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LSL-MYCN;hGFAP-Cre induced tumors is feasible and 
significantly delays tumor cell proliferation in vitro and 
in vivo.
DISCUSSION
The MYC family of transcription factors consists of 
three well characterized members, c-MYC, L-MYC, and 
MYCN. Deregulation of MYC family members is often 
associated with aggressive tumor behavior and therapy 
resistance, and MYC overexpression in amplified tumors 
represents a therapeutic challenge in many malignancies 
including neuroblastoma [20]. We here describe a novel 
model for MYCN-driven tumors that are induced by 
targeting MYCN to GFAP-positive cells in transgenic 
mice. These tumors were of neuroendocrine origin and 
were located either in the pancreas, the pituitary gland or 
both (Figure 1C). The neuroendocrine nature of the tumors 
was revealed by immunostaining for the neuroendocrine 
marker chromogranin A (Figure 2D) and confirmed by 
global expression profiling. The incidence of tumor 
formation in our model was considerably lower than in 
other hGFAP-Cre driven transgenic models, in which 
penetrance was 100% (hGFAP-Cre x LSL-SmoM2; 
Schüller et al., Cancer Cell 2008). This suggests that, in 
general, Cre-mediated excision should be sufficient to 
achieve a tumor penetrance of 100%, but also that MYCN 
expression may be variable and that a threshold sufficient 
for tumor development may not be reached in tumor-
free LSL-MYCN;hGFAP-Cre mice. This is supported 
by the finding that MYCN levels are undetectable or low 
in target organs in tumor-free animals (Figure 1F-1G). 
Alternatively, additional hits that have not occurred in 
tumor-free mice may be required for tumor development. 
The latter is corroborated by the long latency period until 
tumor formation becomes evident ( > 6 months). However, 
a potential “second hit” could not be identified yet.
It has been reported that α-cells of the Langerhans 
islets express GFAP [21,22]. As these α-cells are the 
main source of glucagon and tumor-bearing LSL-
MYCN;hGFAP-Cre mice displayed with elevated 
blood glucagon levels as well as Glucagon-positive 
tumors, these findings are in line with the diagnosis of 
a glucagon-producing PanNET. Expression profiling of 
tumors confirmed marker expression of neuroendocrine 
tumors and revealed for the first time a comprehensive 
view on mRNA patterns in those tumors. Moreover, 
the role of MYC proteins as transcriptional amplifiers 
has been suggested by studies demonstrating that MYC 
overexpression increases the total amount of RNAs both 
in tumor cells as well as in physiological settings [1,23]. 
Later, it has been described that oncogenic MYCN acts 
more specific in shaping the transcriptional profile [2]. 
This is supposed to explain the emergence of pathway 
specific signatures related to MYCN by a secondary 
RNA amplification model ([24], reviewed in [25]). 
However, small sample size of our dataset does not 
allow discriminating between MYCN-induced general 
transcriptional amplification and enrichment of MYCN-
specific functional target gene clusters. 
In humans, most glucagon-producing PanNETs 
occur sporadically (87%) and only rarely as a component 
of the multiple endocrine neoplasia syndrome type 1 
(MEN1). In a series of human tumors (n = 9) we here 
showed that MYCN is expressed on mRNA level in a 
subset of these tumors (Figure 3D), while no MYCN or 
c-MYC amplifications were detected by FISH analyses 
(data not shown). Of the glucagon-producing PanNETs, 
only a fraction is associated with a hormonal syndrome 
and these are called glucagonomas. They have an 
incidence of 1 in 20 million [26] with an average age at 
diagnosis of 52.5 years [27]. Almost all glucagonomas and 
glucagon-producing PanNETs arise in the pancreas (97%) 
with only a few tumors being localized extrapancreatically 
in kidney, duodenum or liver. Most patients with a 
glucagonoma syndrome develop a so called “necrolytic 
migratory erythema”, diarrhea, weight loss, diabetes and 
thromboembolic problems [28], [26,29]. It is of interest to 
note that mice frequently presented with ruffled fur during 
onset of tumor formation, which might have had its cause 
in skin irritations comparable to necrolytic migratory 
erythema characterizing human glucagonoma patients 
[28].
The combined appearance of pituitary tumors 
together with glucagon producing PanNETs is reminiscent 
of a MEN1 syndrome, in which PanNETs commonly 
go together with parathyroid and pituitary tumors 
[30]. However, our LSL-MYCN;hGFAP-Cre double 
transgenic animals did not develop parathyroid tumors. 
Moreover, array-CGH analyses of tumors in transgenic 
mice did not suggest involvement of the MEN1 locus 
on mouse chromosome 19, which is syntenic to human 
chromosome 11q13. Additionally, MEN1 gene expression 
was not down-regulated in tumors, rendering mutational 
inactivation of the MEN1 gene unlikely. Finally, it 
remains to be determined, if the spectrum of the human 
MEN1-syndrome can be fully recapitulated in mice, 
since glucagon cell specific deletion of MEN1 in mice 
resulted in the development of insulinomas [31] and not 
glucagon producing cells. The only other MYCN-driven 
animal model of MYCN-induced PanNETs was described 
in zebrafish, yet the developing tumors were similar to 
human insulinomas [32]. PanNETs expressing glucagon 
have also been described in mice with a deletion of the 
glucagon receptor [33], or with a conditional deletion of 
p53 and Rb [15].
Regarding the question as to whether the presented 
mouse model can be used for the evaluation of new 
MYCN-directed therapies, it is of note that transcriptome 
analyses of the MYCN-GFAP induced tumors revealed 
a previously described MYCN-related expression 
signature (Figure 4) [7]. This suggested that MYCN 
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governs the overall expression profile and may function 
as an oncogenic driver in our mouse model. As MYC 
proteins themselves are hardly druggable, many efforts 
have been put into the identification of downstream and 
upstream regulators of MYC family members. Functional 
screens have identified Brd proteins, most prominently 
Brd4, and Aurora kinase A as important check points of 
MYCN transcription and protein turnover, respectively 
[16,34]. Therefore, we checked, whether tumor growth 
depended on MYCN function by JQ1 and MLN8237 in 
xenografts and in cell lines. For this purpose, stable cell 
lines were established from pancreatic tumors of LSL-
MYCN;hGFAP-Cre mice. Although there is a late onset 
of primary tumor development in this model (Figure 
1A), and tumor growth appears to be slow, tumor-
derived cell lines proliferate quickly both in vitro and 
as xenografts in immunocompromised mice (Figure 5A, 
5B). Both, cell lines and xenografts responded to JQ1 and 
MLN8237 treatment and present with reduced MYCN 
levels on mRNA and protein levels at the end of the 
therapy. JQ1 down-regulates Brd4-triggered expression 
of MYCN target genes [18] and this due, at least in part, 
to interference with Brd4-binding to super-enhancer 
modules [35]. As MYCN is expressed in our model from 
a transgenic cassette lacking the super-enhancer module 
present in the MYCN genomic region, we assume an 
indirect effect of JQ1 on MYCN expression levels. This 
could be caused by general reduction of transcription 
in regressing tumors induced by JQ1. In xenografts, an 
increased apoptosis rate and decreased proliferation were 
found (Figure 5F-5G), which is in line with reports on 
other solid tumors including neuroblastoma [7] and JQ1-
treated experimental medulloblastoma [36]. These findings 
indicate that MYC proteins are required for both tumor 
initiation and maintenance of the malignant phenotype and 
corroborate the notion that indirect inhibition of MYCN 
by targeting Brd-proteins or Aurora A is a promising 
therapeutic strategy in MYCN-dependent tumors across 
entities. However, MYC proteins themselves may 
modulate resistance to JQ1, which has been recently 
described for pancreatic cancer cells up-regulating c-MYC 
in response to JQ1 [37]. Thus, we here not only describe 
a novel transgenic model for neuroendocrine tumors, 
but also provide a framework for the evaluation of new, 
MYCN-directed therapies.
MATERIALS AND METHODS
Animals
Conditional expression of MYCN was 
achieved by crossbreeding mice carrying a floxed 
polyA stretch upstream of MYCN sequences (LSL-MYCN, 
[7]) with mice expressing Cre recombinase specifically in 
GFAP-positive cells (hGFAP-Cre, [38]). Hence, activation 
of MYCN and a second open reading frame coding for the 
luciferase gene (Fluc) in LSL-MYCN;hGFAP-Cre double 
transgenic animals was restricted to GFAP-positive cells 
expressing Cre recombinase. As the single transgenic 
animals derive from different strains, double transgenic 
animals had a mixed genetic background (FvB/ 129 SvJ 
x B6). Mice were genotyped for presence of transgenic 
cassettes and functional activity of Cre recombinase 
in targeted cells was proven by a “flox-out” PCR as 
described [7]. As the luciferase reporter (Fluc) is expressed 
downstream of the MYCN transgene, in vivo and ex vivo 
imaging of animals, cells and tissues was performed using 
a VEVO2100 device (VisualSonics). Additionally, tumor 
formation was monitored by abdominal palpation.
Pathology assessment
Mice were euthanized by isoflurane and CO2 
inhalation followed by cervical dislocation according to 
the local guidelines for animal handling. Necropsy was 
performed to macroscopically detect tumor formation. 
Samples of tissues were collected from multiple sites 
and organs and were either snap frozen or fixed in 4% 
paraformaldehyde for further analyses.
Analyses of human PanNETs
Tissues sections from human PanNETs were 
evaluated by at least two independent pathologists to 
confirm the diagnosis taken from medical records. Use of 
patient material for the purpose of this study was approved 
by the Ethics committee at University of Duisburg-
Essen. Macrodissection of formalin-fixed paraffin 
embedded (FFPE) histology blocks was performed to 
separately harvest tumor and surrounding normal tissue 
for subsequent RNA analyses. RNA was extracted using 
a RNeasy FFPE kit (QIAGEN, Hilden, Germany) using a 
previously described protocol [39]. Specific primers for 
amplification of the target gene, MYCN, by quantitative 
RT-PCR were designed to generate short amplicons 
accounting for partial degradation of RNA in FFPE 
samples. Results were normalised to the expression of 
β-Actin and tumors were evaluated as MYCN-positive 
if normalised MYCN expression was > 5 % than that of 
the positive control (a neuroblastoma cell line with high 
MYCN expression) and if the corresponding normal tissue 
obtained from the same FFPE sample was negative for 
MYCN gene expression.
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Western blotting, immunohistochemistry and 
glucagon ELISA
Organs and tumors were either snap frozen or 
fixed in 4% paraformaldehyde for at least 24 hours. 
Detection of MYCN in tumors was achieved using 
Western Blot analysis. In brief, tissue slices were lysed 
on ice in RIPA buffer (50mM HEPES, 10mM NaCl, 1% 
NP-40, 1% TritonX-100 and 0.1% SDS) supplemented 
with protease inhibitors (Roche). Separation of proteins, 
transfer to membranes and subsequent incubation with 
anti-MYCN antibody (#9405, 1:1000, Cell Signaling) 
was performed as described [7] .For histology, 4 µm 
sections were cut from paraffin blocks and stained with 
hematoxylin and eosin (H&E), Ki 67 (#ab16667, 1:100, 
Abcam), cleaved Caspase-3 (5A1E, 1:100, Cell Signaling, 
9664S), Glucagon (#NCL-GLUCp, Novocastra) and 
Chromogranin A (#ab 15160, Abcam). Photomicrographs 
were recorded using a NanoZoomer 2.0HT (Hamamatsu 
Photonics Deutschland GmH, Herrsching, Germany). 
Glucagon levels in the serum of tumor-bearing or tumor-
free animals were determined using a commercially 
available glucagon-specific ELISA (Mercodia, Uppsala, 
Sweden).
mRNA expression profiling and pathway analyses
Total RNA was isolated from primary murine 
pancreatic and pituitary tumors, processed and hybridized 
to Affymetrix MG-430_2.0 oligonucleotide microarrays 
according to the manufacturer’s protocol. Normalization 
of array data and identification of differentially expressed 
genes was achieved using Partek Genomics Suite (Partek, 
Michigan, MI). Furthermore, global gene expression 
analysis was performed using the R platform (version 
3.1.1, http://www.r-project.org) and the following 
packages: arrayQualityMetrics (version 3.20.0), affy 
(version 1.42.3), limma (version 3.20.9) and vegan 
(version 2.2-1). To pre-process Affymetrix arrays, RMA 
from the affy package was used. In addition, gene set 
enrichment analysis (GSEA) was run on curated MSigDB 
gene sets and pathway activity scores calculated according 
to [40] using the MYCN signatures defined in [7] (and 
references herein). Briefly, genes were ranked for each 
sample and genes contained in the signature were summed 
for each tumor. The rank sums were divided by the average 
overall rank sum and log2 transformed. Student’s t-test 
was used to determine significant differences between the 
pathway activity scores for different tumor groups.
Establishing cell lines from tumors of LSL-
MYCN;hGFAP-Cre mice
Pancreatic tumors were minced manually with 
scissors and incubated in Liberase DL (Roche) at 37°C 
for 30 minutes. After centrifugation, tumor cells in the 
supernatant were maintained in DMEM medium, 10% 
FCS, antibiotics (1%), L-Glutamin (1%) and sodium 
pyruvate (1%) for 24 hours. Long-term cultivation 
of tumor cells was feasible and resulted in a cell line 
designated Pank4. Single cell clones were generated from 
these cells by limited dilution. Two stable cell clones were 
termed IC11 and IIID2, which had differentiated and 
undifferentiated morphology, respectively. 
Indirect MYCN inhibition by JQ1 and MLN 8237 
in vitro and in vivo
Pank4 cells were seeded into 96-well plates and 
treated with JQ1 and MLN 8237 for 72 hours. Metabolic 
activity was analysed with 3-[4,5-dimethylthiazol-3-yl]-
2,5-diphenyltetrazolium bromide (MTT) assay, and used 
as surrogate for the number of living cells. For in vivo 
experiments, six-week old female athymic NCR (nu/nu) 
mice were inoculated subcutaneously with 4x106 Pank4 
tumor cells that were suspended in 250 µl Matrigel 
(Becton Dickinson, Heidelberg, Germany). Tumor growth 
was controlled daily and tumor volume was calculated 
using the formula (breadth x length x height)/2. In vivo 
luciferase imaging for tumor visualization was performed 
as described previously [7]. Once that tumor volume 
exceeded 300 mm3, mice were randomly assigned to 
one of three groups and were treated daily with either 
MLN 8237 (30 mg per kg body weight), JQ1 (50 mg 
per kg body weight) or vehicle control (12.5% DMSO in 
glucose). MLN 8237 was administered orally, JQ1 and the 
vehicle control (DMSO) via intraperitoneal injection. The 
animals were sacrificed once the tumor reached a volume 
of 1500 mm3. For evaluation of on target efficacy, animals 
were treated twice daily for three days, once the tumor 
volume exceeded 100 mm3. These animals were sacrificed 
four hours following the last treatment, and tumor tissue 
was divided and either snap-frozen in liquid nitrogen 
and stored at -80°C, or fixed in formalin and paraffin-
embedded for immunohistochemistry. 
Statistical analyses
Statistical analyses were performed using Graph 
Pad Prism 5.0 (Graph Pad Software Inc., San Diego, CA, 
USA). Overall survival was visualized through Kaplan-
Meier analyses. Mean relative proliferation was calculated 
by Ki-67 expression and mean relative apoptosis by 
positive staining of cleaved caspase 3, in transplanted 
Oncotarget74425www.impactjournals.com/oncotarget
LSL-MYCN;hGFAP-Cre cell lines from control, JQ1- 
and MLN 8237- treated groups of mice, using three 
representative images of each tumor. Significance was 
calculated by Student’s t-test (*, p < 0.05; **, p < 0.01; 
***, p < 0.001).
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